A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)

被引：0
|
作者：
Davis, Alison [1 ]
Albayya, Faris [1 ]
Lobbardi, Riadh [1 ]
Palmer, Michael [1 ]
Sherwin, Cori Ann [1 ]
Green, Sara [1 ]
Stevison, Faith [1 ]
Kim, Sean [1 ]
Wilkie, Gordon [1 ]
Kadambi, Vivek [1 ]
Dorsch, Marion [1 ]
Boral, Andy [1 ]
LaBranche, Timothy [1 ]
Hurtt, Mark [2 ]
Schwabb, Robert [3 ]
Stewart, Rachel [4 ]
Lyon, Morgan [4 ]
Pauplis, Rachel [4 ]
机构：
[1] Blueprint Med, Cambridge, MA USA
[2] Hurtt Consulting, Groton, CT USA
[3] Celerion, Lincoln, NE USA
[4] Invicro, Boston, MA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB SUN-108
引用
收藏
页码：290 / 290
页数：1
相关论文
共 35 条
  • [1] BLU-782; a highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
    Davis, Alison
    Hodous, Brian
    Labranche, Timothy
    Sheets, Michael
    Brooijmans, Natasja
    Kim, Joseph
    Williams, Brett
    Kim, Sean
    Xu, Lan
    Vassiliadis, John
    Zhu, Julia
    Wang, Ruduan
    Stewart, Rachel
    Fleming, Paul
    Graul, Chris
    Greenblatt, Elliot
    Bouchard, Keith
    Kadambi, Vivek
    Guzi, Timothy
    Hunter, Jeffrey
    Lengauer, Christoph
    Dorsch, Marion
    Garner, Andrew
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 26 - 26
  • [2] An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva
    Davis, Alison J.
    Brooijmans, Natasja
    Brubaker, Jason D.
    Stevison, Faith
    LaBranche, Timothy P.
    Albayya, Faris
    Fleming, Paul
    Hodous, Brian L.
    Kim, Joseph L.
    Kim, Sean
    Lobbardi, Riadh
    Palmer, Michael
    Sheets, Michael P.
    Vassiliadis, John
    Wang, Ruduan
    Williams, Brett D.
    Wilson, Douglas
    Xu, Lan
    Zhu, Xing Julia
    Bouchard, Keith
    Hunter, Jeffrey W.
    Graul, Chris
    Greenblatt, Elliot
    Hussein, Amira
    Lyon, Morgan
    Russo, Joelle
    Stewart, Rachel
    Dorsch, Marion
    Guzi, Timothy J.
    Kadambi, Vivek
    Lengauer, Christoph
    Garner, Andrew P.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2024, 16 (749)
  • [3] Revealing Activation Mechanism of Alk2 Kinase Mutations in Fibrodysplasia Ossificans Progressiva (FOP)
    Alsamarah, Abdelaziz
    Hao, Jijun
    Luo, Yun
    [J]. BIOPHYSICAL JOURNAL, 2016, 110 (03) : 206A - 206A
  • [4] Rational design of ALK2 small molecule inhibitors for treatment of fibrodysplasia ossificans progressiva (FOP)
    Luo, Yun
    Alsamarah, Abdelaziz
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [5] A constitutively activated BMP receptor, ALK2, induces heterotopic bone formation in patients with Fibrodysplasia Ossificans Progressiva (FOP)
    Fukuda, T.
    Kohda, M.
    Kanomata, K.
    Nojima, J.
    Kamizono, J.
    Oda, H.
    Nakayama, K.
    Ohtake, A.
    Miyazono, K.
    Jimi, E.
    Owan, I.
    Okazaki, Y.
    Katagiri, T.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S10 - S10
  • [6] Preclinical Characterization of BCX9250, a Potent Oral Activin receptorlike kinase-2 (ALK2) Inhibitor, for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
    Chen, Xilin
    Cheng, Xiaogang
    Kallogg-Yelder, Debra
    Liu, Qinde
    Muppa, Saritha
    Parker, Cynthia
    Raman, Krishnan
    Kotian, Pravin
    Babu, Yarlagadda
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 96 - 96
  • [7] ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma
    Sekimata, Katsuhiko
    Sato, Tomohiro
    Sakai, Naoki
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2020, 68 (03) : 194 - 200
  • [8] Molecular dynamics study of ALK2 kinase mutations in fibrodysplasia ossificans progressiva disorder
    Luo, Yun
    Alsamarah, Abdelaziz
    Hao, Jijun
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [9] Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva
    Chaikuad, Apirat
    Alfano, Ivan
    Kerr, Georgina
    Sanvitale, Caroline E.
    Boergermann, Jan H.
    Triffitt, James T.
    von Delft, Frank
    Knapp, Stefan
    Knaus, Petra
    Bullock, Alex N.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (44) : 36990 - 36998
  • [10] Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells
    Sanchez-Duffhues, Gonzalo
    Williams, Eleanor
    Benderitter, Pascal
    Orlova, Valeria
    van Wijhe, Michiel
    de Vinuesa, Amaya Garcia
    Kerr, Georgina
    Caradec, Josselin
    Lodder, Kirsten
    de Boer, Hetty C.
    Goumans, Marie-Jose
    Eekhoff, Elisabeth M. W.
    Morales-Piga, Antonio
    Bachiller-Corral, Javier
    Koolwijk, Pieter
    Bullock, Alex N.
    Hoflack, Jan
    ten Dijke, Peter
    [J]. JBMR PLUS, 2019, 3 (11)
1234